Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;84(5):273-80.
doi: 10.4174/jkss.2013.84.5.273. Epub 2013 Apr 24.

Neoadjuvant human epidermal growth factor receptor-2 targeted therapy in patients with locally advanced breast cancer

Dong Hui Cho  1 , Se Kyung Lee, Sangmin Kim, Min-Young Choi, Seung Pil Jung, Jeonghui Lee, Jiyoung Kim, Min Young Koo, Soo Youn Bae, Jung-Han Kim, Jee Soo Kim, Kil Won Ho, Jeong Eon Lee, Seok Jin Nam, Jung-Hyun Yang
Affiliations

Neoadjuvant human epidermal growth factor receptor-2 targeted therapy in patients with locally advanced breast cancer

Dong Hui Cho et al. J Korean Surg Soc. 2013 May.

Abstract

Purpose: We analyzed the responses of patients with locally advanced breast cancer to neoadjuvant chemotherapy (NAC) and NAC combined with neoadjuvant human epidermal growth factor receptor-2 (HER2) targeted therapy (NCHTT).

Methods: We retrospectively reviewed 59 patients with HER2 amplified locally advanced breast cancer among patients who were treated surgically after neoadjuvant therapy at Samsung Medical Center between 2005 and 2009. Thirty-one patients received conventional NAC and 28 patients received NCHTT. Pathologic responses were assessed according to response evaluation criteria in solid tumors (RECIST) guidelines.

Results: Pathologic complete response (pCR) was achieved in 13 out of 28 patients treated with NCHTT and in 6 out of 31 patients treated with NAC alone (46.4% vs. 19.4%, respectively, P = 0.049). Breast conserving surgery (BCS) was more frequently performed in the NCHTT group than in the NAC only group (71.4% vs. 19.4%, P < 0.001). The 3-year recurrence-free survival (RFS) rate was 100% in the NCHTT group and 76.4% in the NAC group (P = 0.014). Together, NCHTT, type of operation (BCS vs. mastectomy) and pathologic nodal status were significant prognostic factors for RFS in univariate analysis.

Conclusion: We found that NCHTT produced higher pCR rates than NAC alone in locally advanced breast cancer.

Keywords: Breast neoplasms; ErbB-2; Neoadjuvant therapy; Response.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Recurrence-free survival (RFS) curve for advanced breast cancer patients treated by neoadjuvant chemotherapy combined with neoadjuvant human epidermal growth factor receptor 2 targeted therapy (NCHTT) and neoadjuvant chemotherapy (NAC).
Fig. 2
Fig. 2
Overall survival (OS) curve for advanced breast cancer patients treated by neoadjuvant chemotherapy combined with neoadjuvant human epidermal growth factor receptor 2 targeted therapy (NCHTT) and neoadjuvant chemotherapy (NAC).
See this image and copyright information in PMC

References

    1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717. - PubMed
    1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130. - PubMed
    1. De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol. 1978;1:53–59. - PubMed
    1. Rubens RD, Sexton S, Tong D, Winter PJ, Knight RK, Hayward JL. Combined chemotherapy and radiotherapy for locally advanced breast cancer. Eur J Cancer. 1980;16:351–356. - PubMed
    1. Kantarjian HM, Hortobagyi GN, Smith TL, Blumenschein GR, Montague E, Buzdar AU, et al. The management of locally advanced breast cancer: a combined modality approach. Eur J Cancer Clin Oncol. 1984;20:1353–1361. - PubMed